SARS News and Research

RSS

O-glycosylation of SARS-CoV-2 spike protein in insect and human cell lines

The mapping of O-glycosites requires instruments that can support electron transfer dissociation (ETD) fragmentation. In a new study published on the bioRxiv preprint server, researchers report their results on whether O-glycosylation patterns affect immunogens for vaccine development.

18 Feb 2021

Could measles virus vectors be used for a new COVID-19 vaccine?

A research team at the Institut Pasteur in France describes the successful development of such a vaccine utilizing a measles virus vector.

18 Feb 2021

Restricting testing to 'classic triad' of symptoms may have missed some COVID-19 cases

Extending the symptoms that trigger a PCR test for COVID-19 could help detect around a third more cases of the disease.

18 Feb 2021

Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities

Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.

18 Feb 2021

Clinical trial launched to analyze bovine-derived immunoglobulins for preventing COVID-19 side effects

The Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, the University of California-Davis and the University of Texas have launched a clinical trial to analyze how useful a food supplement can be for preventing the worst side effects of COVID-19.

18 Feb 2021

How has 3D printing come to the aid of healthcare during the COVID-19 pandemic?

In the study, published in the journal Emergent Materials, the researchers identified the role of 3D printing in COVID-19. During the pandemic, over 100 various 3D printable PPE designs have been used.

18 Feb 2021

A glycan controls how SARS-CoV-2’s spike protein opens, study finds

Using simulations, a team of researchers in the U.S. found that the glycan at position N343 of the SARS-CoV-2 spike protein’s receptor-binding domain (RBD) helps in its opening. A mechanism that aids its binding to the host cell receptor.

18 Feb 2021

Endothelial SARS-CoV-2 infection induces proinflammatory responses without supporting viral amplification, finds study

A team of scientists from Australia and Brazil recently investigated the involvement of endothelial cells in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

18 Feb 2021

Researchers evaluate frequency of SARS-CoV-2 in hematology/oncology settings

18 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

How have COVID-19 pandemic school closures impacted the health of children globally?

A new study by researchers in the US and the UK explores the damage caused by school closures to educational progress, health, and well-being in children and young people globally.

18 Feb 2021

Are antibody cocktails the key to COVID-19 treatment?

News-Medical speaks to Dr. Natalia Freund about her latest research into COVID-19, and how most people are capable of producing neutralizing antibodies against the virus.

18 Feb 2021

New diagnostic platform can rapidly measure COVID-19-related biomarkers

The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute's eRapid technology with the company's proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.

18 Feb 2021

Engineered peptide can reduce severe COVID-19 infection in humans

An engineered peptide given to ferrets two days before they were co-housed with SARS-CoV-2-infected animals prevented virus transmission to the treated ferrets, a new study shows.

18 Feb 2021

SARS-CoV-2 variants of concern drive up infections by 15-40 percent in Germany

As the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to distress worldwide, new variants are emerging that threaten the possibility of containment by current vaccines or therapeutic antibodies.

18 Feb 2021

CDC study says face mask mandates reduced COVID-19 hospitalizations in the U.S.

A new study by researchers at the CDC examined whether the implementation of the mask mandate is tied to COVID-19-related hospitalization growth rates among different age groups.

17 Feb 2021

Advancements in DNA vaccines against COVID-19

The rapid spread of the pathogen and the increasing number of cases highlight the need for an effective and safe vaccine. As vaccination efforts roll out in many countries, new types of vaccines, like deoxyribonucleic acid (DNA) vaccines, are under research..

17 Feb 2021

Convalescent plasma shows CD8+ T cell responses to SARS-CoV-2 variants

Researchers in the United States have conducted a study suggesting that individuals who have recovered from or been vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) should maintain effective CD8+ T-cell responses against the major variants that have recently emerged.

17 Feb 2021

Where might future novel coronaviruses come from?

The researchers predicted many more associations between coronaviruses and host species than have been observed to date. They also predicted 30 times more potential recombination hosts of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Feb 2021

Nasal antiviral blocks SARS-CoV-2 transmission in ferrets

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus, including recent variants.

17 Feb 2021